白细胞端粒长度缩短与2型糖尿病血糖进展相关:一项前瞻性及孟德尔随机化分析
在香港糖尿病登记处5,506例连续中国2型糖尿病患者中,检测基线相对白细胞端粒长度(rLTL)并随访8.8年,发现rLTL较短者需起始外源性胰岛素的风险更高(每降低1单位HR=1.10,95%CI 1.06-1.14),孟德尔随机化分析支持因果关联,提示端粒长度可能是血糖进展的生物标志物。
要点
- 基线rLTL较短者随访期间需胰岛素治疗的风险更高,校正混杂因素后仍显著。
- 每降低1单位rLTL,血糖进展风险HR=1.10(95%CI 1.06-1.14)。
- 孟德尔随机化分析支持rLTL降低与糖尿病进展风险升高存在关联。
核心结论
- 在2型糖尿病患者中,较短的rLTL与血糖进展风险升高显著相关,且独立于已知危险因素。
- 端粒长度可能是2型糖尿病血糖进展的有用生物标志物。
研究设计与样本
- 研究为队列研究,纳入香港糖尿病登记处5,506例连续中国2型糖尿病患者,基线DNA可获取且有随访数据。
- rLTL采用定量PCR检测;血糖进展定义为新需要外源性胰岛素。
- 另进行两样本孟德尔随机化分析。
主要发现
- 5,349例受试者平均(SD)年龄57.0(13.3)岁,平均(SD)随访8.8(5.4)年。
- 1,803例进展至需要胰岛素者的基线rLTL显著短于其余受试者(4.43±1.16 vs. 4.69±1.20)。
- rLTL每降低1单位(至约0.2千碱基),血糖进展风险HR=1.10(95%CI 1.06-1.14),校正混杂因素后仍显著。
- 基线rLTL与随访期间血糖暴露独立相关(β=-0.05,95%CI -0.06至-0.04)。
- 绝对LTL每降低1千碱基,糖尿病进展风险平均为1.69倍(95%CI 1.35-2.11);孟德尔随机化分析显示遗传决定的rLTL每降低1单位,糖尿病进展风险为1.38倍(95%CI 1.12-1.70)。
临床怎么用
- 原文结论认为端粒长度可能是2型糖尿病患者血糖进展的有用生物标志物,未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several studies support associations between relative leukocyte telomere length (rLTL), a biomarker of biological aging and type 2 diabetes. This study investigates the relationship between rLTL and the risk of glycemic progression in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this cohort study, consecutive Chinese patients with type 2 diabetes (N = 5,506) from the Hong Kong Diabetes Register with stored baseline DNA and available follow-up data were studied. rLTL was measured using quantitative PCR. Glycemic progression was defined as the new need for exogenous insulin. RESULTS: The mean (SD) age of the 5,349 subjects was 57.0 (13.3) years, and mean (SD) follow-up was 8.8 (5.4) years. Baseline rLTL was significantly shorter in the 1,803 subjects who progressed to insulin requirement compared with the remaining subjects (4.43 ± 1.16 vs. 4.69 ± 1.20). Shorter rLTL was associated with a higher risk of glycemic progression (hazard ratio [95% CI] for each unit decrease [to ∼0.2 kilobases]: 1.10 [1.06-1.14]), which remained significant after adjusting for confounders. Baseline rLTL was independently associated with glycemic exposure during follow-up (β = -0.05 [-0.06 to -0.04]). Each 1-kilobase decrease in absolute LTL was on average associated with a 1.69-fold higher risk of diabetes progression (95% CI 1.35-2.11). Two-sample Mendelian randomization analysis showed per 1-unit genetically decreased rLTL was associated with a 1.38-fold higher risk of diabetes progression (95% CI 1.12-1.70). CONCLUSIONS: Shorter rLTL was significantly associated with an increased risk of glycemic progression in individuals with type 2 diabetes, independent of established risk factors. Telomere length may be a useful biomarker for glycemic progression in people with type 2 diabetes.
引用
- Cheng F, Luk AO, Shi M, et al. Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care. 2022. PMID: 35085380. doi:10.2337/dc21-1609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。